HEPATITIS B TREATMENT VACCINE BASED ON INACTIVATED WHOLE RECOMBINANT HANSENULA CELL WHICH EXPRESSES HBSAG AND HBCAG

摘要

Provided is a hepatitis B treatment vaccine based on an inactivated whole recombinant Hansenula cell which expresses HBsAg and HBcAg. An HBsAgVLP and an HBcAgVLP expressed in the recombinant Hansenula cell are used as antigens, the amino acid sequence of the HBsAg expressed by the recombinant Hansenula contains a total of 19 CTL epitopes, the amino acid sequence of the HBcAg expressed by the recombinant Hansenula contains a total of 19 CTL epitopes, and the inactivated whole recombinant Hansenula cell is used as an adjuvant.